ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors.

http://www.wikidata.org/entity/Q37588391

about

The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors Gastroenteropancreatic high-grade neuroendocrine carcinoma Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.Update on pancreatic neuroendocrine tumors.Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.Care for patients with multiple endocrine neoplasia type 1: the current evidence base.Neuroendocrine neoplasms of the gastrointestinal tract New therapeutic options for metastatic malignant insulinomas.Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.Advancements in pancreatic neuroendocrine tumors.Spinal cord compression after radiolabeled metaiodobenzylguanidine analogue therapy in advanced malignant insulinoma.The treatment of hyperinsulinemic hypoglycaemia in adults: an update.Cross sectional and nuclear medicine imaging of pancreatic insulinomas.Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential Management of the hormonal syndrome of neuroendocrine tumors.Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma."Cherry picking", a multiple non-anatomic liver resection technique, as a promising option for diffuse liver metastases in patients with neuroendocrine tumours.Neuroendocrine tumors diagnosed at the Antonio Cardarelli hospital (Naples, Italy) between 2006-2009: a single-institution analysis.Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases

P2860

Q26740374-27D50781-5FC1-45DE-B7D6-ABA2B926F811 Q26998392-0F9602DF-B110-4AE8-87B7-2768766A8515 Q33648996-0AA5906E-1805-49D3-A9F7-7D1E16FA88DD Q34453043-A42BA614-9E6B-45FD-AC95-62E0AAC917FC Q35201583-9BE9AC7A-4715-42BC-958E-A6EC28DC0561 Q36413831-412AC606-A686-4DB1-A283-23E0D8DDE575 Q36755905-15C22480-3A04-40BE-8BDB-DDE2F0C818EA Q37125550-0277D21B-5B3E-4827-A608-47E2268131B3 Q37688704-B691EF24-A1EA-4F0F-9B11-B8D6D70233F8 Q37702716-4C5BDA02-3EEB-41F7-B033-EFB98B7769E5 Q37765569-BC25A5E7-0879-4B86-AD9A-09722AEE3D55 Q37808142-F9EE9D93-78C0-461E-92AF-FAA3CE5BCE08 Q37883066-3EA57360-9E23-43C8-B6F4-8024CF846D26 Q37886036-38D23650-28BF-4441-8BF6-BC5D545127DE Q38076275-7B58C91F-4373-4296-A75F-78A78004374A Q38099390-56561E3E-DA9A-4A98-A286-FB9C898DF96B Q38125257-1D25CF71-22C7-497C-89B1-70EFF06AAB31 Q38494154-4770B107-29B8-492B-A947-E25F87F7ADA8 Q38953515-B06EA18A-80C9-4D2D-BA5F-D92D7DC241B3 Q38957569-573649FF-409A-4EB4-99D4-D1B93B1A0F31 Q39952447-F15A8F6A-FFA5-4A76-AA5F-02902C5B1969 Q41832570-BD3AA520-186C-4451-AF3F-721F68D2F778 Q42588070-C01EDE4C-1D55-41B9-9602-2966D506BE9C Q43475328-6E738479-A8ED-452A-AE8F-28F6A67AECF4 Q44846366-69875D9B-1CB3-4B9A-9921-95872A007B86 Q57820051-B3B04771-45ED-4D47-80D9-E6C83F798451

P2860

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors.

http://www.wikidata.org/entity/Q37588391

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ENETS Consensus Guidelines for ...... ts with neuroendocrine tumors.

@en

ENETS Consensus Guidelines for ...... ts with neuroendocrine tumors.

@nl

type

label

ENETS Consensus Guidelines for ...... ts with neuroendocrine tumors.

@en

ENETS Consensus Guidelines for ...... ts with neuroendocrine tumors.

@nl

prefLabel

ENETS Consensus Guidelines for ...... ts with neuroendocrine tumors.

@en

ENETS Consensus Guidelines for ...... ts with neuroendocrine tumors.

@nl

P1433

Q37588391-8950877C-1F78-4913-AA43-171DA90C5A1E

P1476

Q37588391-75386AA6-C0FB-4894-AF59-4EC581D17E29

P2093

Q37588391-143D1D1D-CC8C-4B06-90B4-FD558E633C5F

Q37588391-3288580C-A080-47B1-8E9D-7683729BEEA1

Q37588391-3702D3AE-0D5D-4197-9491-BE4D6181D1B1

Q37588391-4F2CE32C-3B45-4D66-90FE-E08EB16BA923

Q37588391-A61E4516-E3E3-4C5C-94EC-D826E357C317

Q37588391-CC23A4A6-03BE-4110-8F53-6D8E84E98689

Q37588391-DAC3310A-09BB-469C-BEA4-B30BAF299E24

Q37588391-DF96C0FB-8BB5-468D-B84F-B132E68E22F4

Q37588391-ED5477F8-9237-4942-8015-53D79BD3C1F1

P304

Q37588391-621C793D-E596-4B8D-9612-85FD4BDEA120

P31

Q37588391-D8AE8B39-0559-4E61-897B-740463DE3CB6

P356

Q37588391-316EAD15-EC14-495E-A6A5-CC3F15B56960

P433

Q37588391-01D2DA20-A4AD-48B5-BE2F-8BBCC34FC78B

P478

Q37588391-9250E00A-4159-4D49-A445-9428D1EC9AA2

P50

Q37588391-2ABD7139-41C7-445F-9CBE-31BAADB4D7B9

Q37588391-35497D47-199F-4BD8-8E8F-61DA03C74DA6

P577

Q37588391-408F17FF-90A5-4C75-874E-C614D65CF41D

P5875

Q37588391-FFDCD23F-D54A-4542-BE55-7C16E66D7D34

P698

Q37588391-1CAA581B-8E13-47F5-9BEC-C8A94327EF38

P921

Q37588391-16621730-DF33-45F1-8090-2913136C6A03

Q37588391-2CC1A09D-5042-46A0-83A0-50B17977738F

Q37588391-8ED66464-FBB2-4881-A2E3-DF24C7287313

P356

P1433

Neuroendocrinology

P1476

ENETS Consensus Guidelines for ...... ts with neuroendocrine tumors.

@en

P2093

Barbro Eriksson

http://www.w3.org/2001/XMLSchema#string

Emilio Bajetta

http://www.w3.org/2001/XMLSchema#string

Emmanuel Mitry

http://www.w3.org/2001/XMLSchema#string

European Neuroendocrine Tumor Society

http://www.w3.org/2001/XMLSchema#string

Mallorca Consensus Conference participants

http://www.w3.org/2001/XMLSchema#string

Marco Platania

http://www.w3.org/2001/XMLSchema#string

Marianne Pavel

http://www.w3.org/2001/XMLSchema#string

Ramon Salazar

http://www.w3.org/2001/XMLSchema#string

Ursula Plöckinger

http://www.w3.org/2001/XMLSchema#string

P304

214-219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000225950

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

European Neuroendocrine Tumor Society

P577

2009-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26773609

http://www.w3.org/2001/XMLSchema#string

P698

19713713

http://www.w3.org/2001/XMLSchema#string

P921

neuroendocrinology